Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Invivyd, Inc.
  6. News
  7. Summary
    IVVD   US00534A1025

INVIVYD, INC.

(IVVD)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
2.100 USD   -7.89%
02/03Invivyd Announces Changes to Executive Team
GL
01/24Morgan Stanley Trims Invivyd Price Target to $2 From $3, Maintains Underweight Rating
MT
01/09Invivyd : J.P. Morgan 41st Annual Healthcare Conference
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Morgan Stanley Downgrades Adagio Therapeutics to Underweight Rating From Equalweight, Adjusts PT to $6 From $11

01/06/2022 | 10:43am EST


ę MT Newswires 2022
All news about INVIVYD, INC.
02/03Invivyd Announces Changes to Executive Team
GL
01/24Morgan Stanley Trims Invivyd Price Target to $2 From $3, Maintains Underweight Rating
MT
01/09Invivyd : J.P. Morgan 41st Annual Healthcare Conference
PU
01/09Invivyd, Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2022Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways ..
GL
2022Invivyd Presented Joint Industry Rationale on Potential Expedited Development Pathways ..
AQ
2022Invivyd, Inc.(NasdaqGM:IVVD) added to NASDAQ Biotechnology Index
CI
2022Invivyd Names Jeremy Gowler as Chief Operating, Commercial Officer
MT
2022Invivyd, Inc. : Change in Directors or Principal Officers, Other Events, Financial Stateme..
AQ
2022Invivyd Appoints Jeremy Gowler as Chief Operating and Commercial Officer, Promotes Pete..
GL
More news
Analyst Recommendations on INVIVYD, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -238 M - -
Net cash 2022 381 M - -
P/E ratio 2022 -0,96x
Yield 2022 -
Capitalization 229 M 229 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 102
Free-Float 72,5%
Chart INVIVYD, INC.
Duration : Period :
Invivyd, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVIVYD, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Last Close Price 2,10 $
Average target price 2,75 $
Spread / Average Target 31,0%
EPS Revisions
Managers and Directors
David Hering Chief Executive Officer & Director
Frederick W. Driscoll Chief Financial & Accounting Officer
Marc W. Elia Chairman
Laura Walker Chief Scientific Officer
Rebecca L. Dabora Chief Technology & Manufacturing Officer
Sector and Competitors
1st jan.Capi. (M$)
INVIVYD, INC.40.00%229
REGENERON PHARMACEUTICALS, INC.4.12%83 640
VERTEX PHARMACEUTICALS5.19%77 269
WUXI APPTEC CO., LTD.15.80%40 679
BIONTECH SE-5.43%34 523
BEIGENE, LTD.16.80%26 752